Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Raymond James Downgrades CME Group to Market Perform

Raymond James Downgrades CME Group to Market Perform

Raymond James analyst Patrick O'Shaughnessy downgrades CME Group (NASDAQ:CME) from Outperform to Market Perform.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Raymond James analyst Patrick O’Shaughnessy downgrades CME Group (NASDAQ:CME) from Outperform to Market Perform.

News

Elon Musk Tweets ‘Beta Expanding To Safety Scores Above 80 After 10.69.2.1 Goes Out’

By Benzinga Newsdesk

September 15, 11:56 AM

https://twitter.com/elonmusk/status/1570441171431985152

TSLA

Why Applied Materials Stock Is Moving Higher After Hours

By Adam Eckert

February 16, 5:14 PM

Applied Materials Inc (NASDAQ: AMAT) shares are rising in Thursday's after-hours session after the company reported better-than-expected financial results and

AMAT

First Light Acquisition Group Inc. Says On December 21, 2022, Bill Weber Resigned From His Position As Co-Chief Executive Officer; As Of Dec 22, 2022, Thomas A. Vecchiolla Will Serve As Sole Chief Executive Officer And Chairman Of Board

By Bill Haddad

December 27, 7:04 AM

-Reuters

FLAG

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022

By Benzinga Newsdesk

December 12, 8:14 AM

– A 92% SVR35 and a 67% TSS50 were Observed in the Efficacy Evaluable Patients at Week 24 – – 57% of Transfusion Independent Patients Achieved Hemoglobin Stabilization – – Company to Host

KPTI

Raymond James Downgrades CME Group to Market Perform

Related Posts

Elon Musk Tweets ‘Beta Expanding To Safety Scores Above 80 After 10.69.2.1 Goes Out’

Why Applied Materials Stock Is Moving Higher After Hours

First Light Acquisition Group Inc. Says On December 21, 2022, Bill Weber Resigned From His Position As Co-Chief Executive Officer; As Of Dec 22, 2022, Thomas A. Vecchiolla Will Serve As Sole Chief Executive Officer And Chairman Of Board

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022